Loading…
Lobbying Spend
—
Filings
12
Firms Hired
1
Active Period
2014–2016
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
2016 · fourth_quarter · Firm: W STRATEGIES, LLC
Issues related to orphan drugs and the value of innovative medicines. March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R. 5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5122
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
2016 · third_quarter · Firm: W STRATEGIES, LLC
Issues related to orphan drugs and the value of innovative medicines. March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R. 5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5122
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
2016 · second_quarter · Firm: W STRATEGIES, LLC
Issues related to orphan drugs and the value of innovative medicines. March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R.5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client expense: — · Firm income: $30,000
Matched citations: H.R.5122
Prescription Drug Affordability Act of 2015
2016 · first_quarter · Firm: W STRATEGIES, LLC
Issues related to orphan drugs and the value of innovative medicines. March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R. 3513: Prescription Drug Affordability Act of 2015.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3513
Prescription Drug Affordability Act of 2015
2015 · fourth_quarter · Firm: W STRATEGIES, LLC
Issues related to orphan drugs and the value of innovative medicines. H.R. 3513: Prescription Drug Affordability Act of 2015.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3513
H.R. 9: Innovation Act, including changes to the Inter Partes Review process at the Patent and Trademark Office (PTO).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 9
Source: Senate LDA